Pointers to cancer prognosis
著者
書誌事項
Pointers to cancer prognosis
(Developments in oncology, 48)
Nijhoff, 1987
大学図書館所蔵 全3件
  青森
  岩手
  宮城
  秋田
  山形
  福島
  茨城
  栃木
  群馬
  埼玉
  千葉
  東京
  神奈川
  新潟
  富山
  石川
  福井
  山梨
  長野
  岐阜
  静岡
  愛知
  三重
  滋賀
  京都
  大阪
  兵庫
  奈良
  和歌山
  鳥取
  島根
  岡山
  広島
  山口
  徳島
  香川
  愛媛
  高知
  福岡
  佐賀
  長崎
  熊本
  大分
  宮崎
  鹿児島
  沖縄
  韓国
  中国
  タイ
  イギリス
  ドイツ
  スイス
  フランス
  ベルギー
  オランダ
  スウェーデン
  ノルウェー
  アメリカ
注記
Includes index
内容説明・目次
内容説明
The last 30 years have seen little improvement in the age-adjusted mortality rates for most common types of cancer, and until we develop more effective and less damaging treatment modalities for these tumours, selection of each patient's treatment must depend on prognostic pointers. These lead to a calculated trade- off between our estimate of likely benefit to the patient, as against cost in terms of quality of life. But changes have occurred recently in our understanding of the traditional prognostic pointers used for selecting such individualised treatment. First, it is increasingly recognised that the stage at which a tumour presents is more related to the chromo logical age of the tumour (how far it has progressed before diagnosis) than to its biological characteristics. While advanced chronological age of the tumour may predict a greater likelihood of early death, only biological criteria can predict the tumour growth rate, the likelihood of prolonged survival, the likely course of the disease after the first recurrence or the likehood of response to systemic therapy. Second, there is increasing use of failure analysis in relating the clinical and biological characteristics of tumours to their response to standard treatments. In the past, the relationship was interpreted mainly in terms of survival rate, but the site and timing of first recurrence and the pattern and timing of subsequent spread provide a better assessment of the control possible from local or systemic therapy.
目次
I. Clinical pointers to prognosis.- 1. Clinical pointers to rapid growth.- 2. Clinical history as a guide to prognosis.- 3. Clinical staging and its prognostic significance.- 4. Prognostic significance of disease-free interval.- 5. Prognostic significance of response to therapy.- 6. Clinical pointers to prognosis in terminal disease.- II. Biological pointers to prognosis.- 7. Biological makers of aggressiveness and invasiveness.- 8. Histopathology and its prognostic significance.- 9. Pointers to metastasis.- 10. Oncofetal and functional antigens in tissue.- 11. Factors in resistance to chemotherapy cure.- 12. Prognostic value of assays of immune competence.- III. Clinical application of prognostic indices.- 13. Prognostic indices in breast cancer.- 14. Prognostic indices in gynecologic cancer.- 15. Prognostic indices in prostatic cancer.- 16. Prognostic indices in lung cancer.- 17. Prognostic indices in mouth and throat cancer.- 18. Prognostic indices in colorectal cancer.- 19. Prognostic indices in stomach cancer.- 20. Prognostic factors in lymphoma.
「Nielsen BookData」 より